Joseph J Eiden
Overview
Explore the profile of Joseph J Eiden including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
18
Citations
501
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Beeslaar J, Mather S, Absalon J, Eiden J, York L, Crowther G, et al.
Vaccine
. 2022 Feb;
40(12):1872-1878.
PMID: 35164991
Background: The MenB-FHbp vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age. The clinical development program included...
2.
Beeslaar J, Absalon J, Anderson A, Eiden J, Balmer P, Harris S, et al.
Infect Dis Ther
. 2020 Jul;
9(3):641-656.
PMID: 32700260
Introduction: Two phase 3 studies in adolescents and young adults demonstrated that MenB-FHbp, a meningococcal serogroup B (MenB) vaccine, elicits protective immune responses after 2 or 3 doses based on...
3.
Vesikari T, Ostergaard L, Beeslaar J, Absalon J, Eiden J, Jansen K, et al.
Vaccine
. 2019 Feb;
37(12):1710-1719.
PMID: 30770221
Background: The period of heightened risk of invasive meningococcal disease in adolescence extends for >10 years. This study aimed to evaluate persistence of the immune response to the serogroup B...
4.
A Longitudinal Epidemiology Study of Meningococcal Carriage in Students 13 to 25 Years Old in Quebec
Gilca R, De Wals P, Nolan S, Kitchin N, Eiden J, Jiang Q, et al.
mSphere
. 2018 Dec;
3(6).
PMID: 30518675
carriage data are necessary to inform serogroup B (NmB) immunization program implementation. This longitudinal study compared detection methods to measure throat carriage prevalence in Quebec from November 2010 to December...
5.
Perez J, Absalon J, Beeslaar J, Balmer P, Jansen K, Jones T, et al.
Expert Rev Vaccines
. 2018 Jun;
17(6):461-477.
PMID: 29883226
Given the characteristics of meningococcal carriage and transmission and the sudden, often severe onset and long-term consequences of disease, vaccination can most effectively provide large-scale control of invasive disease. Six...
6.
Ostergaard L, Vesikari T, Absalon J, Beeslaar J, Ward B, Senders S, et al.
N Engl J Med
. 2017 Dec;
377(24):2349-2362.
PMID: 29236639
Background: MenB-FHbp is a licensed meningococcal B vaccine targeting factor H-binding protein. Two phase 3 studies assessed the safety of the vaccine and its immunogenicity against diverse strains of group...
7.
Donald R, Hawkins J, Hao L, Liberator P, Jones T, Harris S, et al.
Hum Vaccin Immunother
. 2016 Dec;
13(2):255-265.
PMID: 27960595
Neisseria meningitidis serogroup B (MenB) is an important cause of invasive meningococcal disease. The development of safe and effective vaccines with activity across the diversity of MenB strains has been...
8.
Muse D, Christensen S, Bhuyan P, Absalon J, Eiden J, Jones T, et al.
Pediatr Infect Dis J
. 2016 Mar;
35(6):673-82.
PMID: 26974889
Background: Bivalent rLP2086, targeting meningococcal serogroup B, will extend prevention of meningococcal disease beyond that provided by quadrivalent serogroup ACWY vaccines; coadministration with recommended vaccines may improve adherence to vaccine...
9.
Senders S, Bhuyan P, Jiang Q, Absalon J, Eiden J, Jones T, et al.
Pediatr Infect Dis J
. 2016 Feb;
35(5):548-54.
PMID: 26835974
Background: This study in healthy adolescents (11 to <18 years) evaluated coadministration of quadrivalent human papillomavirus vaccine (HPV-4), with bivalent rLP2086, a meningococcal serogroup B (MnB) vaccine. Methods: Subjects received...
10.
Reiner D, Bhuyan P, Eiden J, Ginis J, Harris S, Jansen K, et al.
Vaccine
. 2015 Dec;
34(6):809-13.
PMID: 26707218
Background: The bivalent rLP2086 vaccine is approved in the United States to prevent meningococcal disease caused by Neisseria meningitidis serogroup B (MnB) in individuals aged 10-25 years. The immunogenicity and...